Evidence map›Paper›PMID 31775667›Full record

ArticleBMC cancer2019

Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol.

Zara Steinmeyer, Stéphane Gérard, Thomas Filleron, Stéphanie Lozano, Delphine Brechemier, Gabor Abellan Van Kan, Loic Mourey, Laurence Cristol-Dalstein, Laure De Decker, Yves Rolland and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02806154 (Frailty and Body Composition in the Elderly Cancer Patients Treated With Chemotherapy), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02806154 completednot on this map

Frailty and Body Composition in the Elderly Cancer Patients Treated With Chemotherapy

TypeobservationalSponsorUniversity Hospital, ToulouseRan2017 to 2023Enrolled144ConditionsCancerArmsDEXA
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zara SteinmeyerGeriatric Department, Internal Medicine and Oncogeriatry Unit, University Hospital, Place du Docteur Baylac, TSA 40031, 31059, Toulouse Cedex 9, France.
Stéphane GérardGeriatric Department, Internal Medicine and Oncogeriatry Unit, University Hospital, Place du Docteur Baylac, TSA 40031, 31059, Toulouse Cedex 9, France.
Thomas FilleronDepartment of Biostatistics, Institut Claudius Regaud, IU, CT-O, Toulouse, France.
Stéphanie LozanoGeriatric Department, Internal Medicine and Oncogeriatry Unit, University Hospital, Place du Docteur Baylac, TSA 40031, 31059, Toulouse Cedex 9, France.
Delphine BrechemierGeriatric Department, Internal Medicine and Oncogeriatry Unit, University Hospital, Place du Docteur Baylac, TSA 40031, 31059, Toulouse Cedex 9, France.
Gabor Abellan Van KanGeriatric Department, Internal Medicine and Oncogeriatry Unit, University Hospital, Place du Docteur Baylac, TSA 40031, 31059, Toulouse Cedex 9, France.
Loic MoureyMedical oncology department, Claudius Régaud Institute-Oncopole-Toulouse Cancer University Institute (IUCT-O), 1 avenue Irène Joliot-Curie, 31100, Toulouse, France.
Laurence Cristol-DalsteinOncogeriatry, ICM Val d'Aurelle, Montpellier, France.
Laure De DeckerClinical Gerontology Department, Centre Hospitalier Universitaire de Nantes, F-44000, Nantes, France.
Yves RollandGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), Toulouse, France.
Laurent BalardyGeriatric Department, Internal Medicine and Oncogeriatry Unit, University Hospital, Place du Docteur Baylac, TSA 40031, 31059, Toulouse Cedex 9, France. balardy.l@chu-toulouse.fr.
Institut Claudius Regaud · FRCentre Hospitalier Universitaire de Nantes · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FR

Funding

Ministère des Affaires Sociales, de la Santé et des Droits des Femmes (FR) 15 7831 08
6 · The paper itself

Abstract

backgroundHalf of cancer cases occur in patients aged 70 and above. Majority of older patients are eligible for chemotherapy but evidence for treating this population is sparse and severe toxicities affect more than half of them. Determining prognostic biomarkers able to predict poor chemotherapy tolerance remains one of the major issues in geriatric oncology. Ageing is associated with body composition changes (increase of fat mass and loss of lean mass) independently of weight-loss. Previous studies suggest that body composition parameters (particularly muscle mass) may predict poor chemotherapy tolerance. However, studies specifically including older adults on this subject remain sparse and the majority of them study body composition based on computed tomography (CT) scanner (axial L3 section) muscle mass estimation. This method is to date not validated in elderly cancer patients.

methodsThis trial (Fraction) will evaluate the discriminative ability of appendicular lean mass measured by dual-energy X-ray absorptiometry (DXA) to predict severe toxicity incidence in older cancer-patients treated with first-line chemotherapy. DXA is considered the gold standard in body composition assessment in older adults. Patient's aged ≥70 diagnosed with solid neoplasms or lymphomas at a locally advanced or metastatic stage treated for first-line chemotherapy were recruited. Patients completed a pre-chemotherapy assessment that recorded socio-demographics, tumor/treatment variables, laboratory test results, geriatric assessment variables (function, comorbidity, cognition, social support and nutritional status), oncological risk scores and body composition with DXA. Appendicular lean mass was standardized using evidence based international criteria. Participants underwent short follow-up geriatric assessments within the first 3 months, 6 months and a year after inclusion. Grade 3 to 5 chemotherapy-related toxicities, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) were assessed at each chemotherapy cycle. DISCUSSION: The finding that body composition is associated with poor tolerance of chemotherapy could lead to consider these parameters as well as improve current decision-making algorithms when treating older adults.

trial registrationClinicalTrials.gov Identifier: NCT02806154 registered on October 2016.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBody CompositionBody Mass IndexGeriatric AssessmentNeoplasmsAgedAged, 80 and overAge FactorsComorbidityFemaleHumansIncidenceMaleResearch DesignRisk AssessmentAgedAppendicular lean massCancerChemotherapy toxicityDual energy X-ray absorptiometryLow lean massMuscle mass

Identifiers

PMID31775667
PMCPMC6882112
OpenAlexW2990855077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.